Alios BioPharma Inc. Also see "Alios BioPharma Inc." - Scrip, 1 June, 2009. aims to create an improved version of interferon—the only drug that could be considered a broad-spectrum antiviral—to help patients who do not respond well to currently marketed forms of the protein. Alios also plans to develop a small-molecule drug that can be given orally yet carry out a key function of the interferon response—degrading viral genomes. Such a drug could potentially treat influenza, hepatitis C and B, HIV, and a host of other viruses.
Immune Targeting Systems Ltd. Also see "Immune Targeting Systems Ltd." - Scrip, 1 June, 2009. is developing synthetic...